Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Entegris Inc (ENTG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Entegris Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Entegris Inc trades at $141.25 (market cap $22.14B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Entegris Inc pays a 0.28% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | ENTG | |
|---|---|---|
Market Cap | $39.89B | $22.14B |
Sector | Health | Technology |
52-Week High | $491.22 | $184.00 |
52-Week Low | $278.09 | $68.80 |
Enterprise Value | $38.15B | $25.45B |
Dividend Yield | — | 0.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
ENTG trades at $145.35, down 0.51% today, with technical indicators showing a bearish trend and support at $143. The company reported Q1 2026 EPS of $0.86, beating estimates, but maintains premium valuations with a P/E of 84.02. Revenue has been stable around $3.2B annually, with net income margins improving to 8.18% in 2026. Analyst sentiment remains positive with a $178.40 price target, though recent news highlights volatility and valuation concerns.
Outlook: ENTG benefits from semiconductor industry tailwinds and AI-driven demand, but faces risks from high valuation and market volatility. The stock offers potential upside based on analyst targets, but investors should monitor earnings consistency and competitive pressures in the tech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →
